最近，Trianni在Nature Biotechnology和Nature Drug Discovery发布的“Monoclonal antibody discovery”中提到，Chempartner作为中国唯一授权CRO，能够制造全人源单克隆抗体。这无疑体现了对睿智化学研发水平的高度认可。原文地址：http://trianni.com/wp-content/uploads/2016/09/bioPharmaDealMakers_Trianni_Sept.pdf
我们的关键技术包括
• 无特定抗原（SPF）的动物和多种动物品系
• 对膜蛋白靶点具有优异免疫反应的特定动物品系
• 可获得全人源序列的转基因小鼠
• 针对高同源和保守抗原的创新性的耐受破坏技术
• 具有所有权的基因免疫技术
• 针对G蛋白偶联受体、高同源性以及其它的高难度靶点的广泛和成功的 抗体开发技术
• 高通量的蛋白和细胞水平的筛选平台
• 成熟建立的结合和功能试验
ShangPharma is comprised of a family of companies including China Gateway Biologics, China Gateway Pharmaceutical Development, ChemPartner, ShangPharma Technology and ShangPharma Investment. The group is actively investing, licensing, and forming partnerships to better serve the healthcare industry. ShangPharma aims, through all its divisions, to create an ecosystem that allows close interaction between major hospitals and academic centers, by matching them with pharmas, biotech, and research institutes to enable the success of all.
